Ontology highlight
ABSTRACT: Objectives
There are no published reports for anti-interleukin-5 therapy in children <12 years with asthma. The primary objective of this study was to characterize the pharmacokinetics and pharmacodynamics of mepolizumab following subcutaneous (SC) administration in children 6 to 11 years-of-age with severe eosinophilic asthma.Hypothesis
Mepolizumab SC pharmacokinetics and pharmacodynamics in children with severe eosinophilic asthma are comparable with adults.Study design
Multinational, nonrandomised, open-label (NCT02377427).Patient selection
Children 6 to 11 years-of-age with severe eosinophilic asthma (blood eosinophil count ≥150 cells/µL at screening or ≥300 cells/µL <12 months of screening) and ≥2 exacerbations in the prior year.Methodology
Chil
SUBMITTER: Gupta A
PROVIDER: S-EPMC6972599 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature